Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Valeric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.70 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.74 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.70 |
| ▸ | PPARG | P37231 | 7/20 | 0.70 |
| ▸ | PPARD | Q03181 | 7/20 | 0.70 |
| ▸ | PPARA | Q07869 | 7/20 | 0.70 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.70 |
| ▸ | TSHR | P16473 | 4/20 | 0.70 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.70 |
| ▸ | TLR2 | O60603 | 2/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.70 |
| ▸ | FABP4 | P15090 | 2/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.70 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.70 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.70 |
| ▸ | PDE4A | P27815 | 1/20 | 0.70 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Valeric Acid SCHEMBL386697 | 1.00 | AKR1B1 (0.74) | AKR1B1GPR84PPARGPPARDPPARA | |
| Valeric Acid SCHEMBL28060341 | 1.00 | AKR1B1 (0.74) | AKR1B1GPR84PPARGPPARDPPARA | |
| Valeric Acid SCHEMBL566579 | 0.95 | AKR1B1 (0.67) | AKR1B1GPR84PPARGPPARDPPARA | |
| Valeric Acid SCHEMBL1237974 | 0.95 | FFAR3 (0.68) | AKR1B1GPR84PPARGPPARDPPARA | |
| Valeric Acid SCHEMBL2553774 | 0.94 | AKR1B1 (0.74) | AKR1B1GPR84PPARGPPARDPPARA | |
| Valeric Acid SCHEMBL30381737 | 0.94 | — | — | |
| Valeric Acid SCHEMBL30442925 | 0.94 | — | — | |
| Valeric Acid SCHEMBL1331662 | 0.94 | — | — | |
| Valeric Acid SCHEMBL5886 | 0.94 | — | — | |
| Valeric Acid SCHEMBL1333240 | 0.94 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1303 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114058279-B | Curved screen protective film, preparation method and application thereof | 安徽屹珹新材料科技有限公司 | 2023-12-08 | — | — | CN | claimed |
| US-11723873-B2 | Oral dosage form of ticagrelor and preparation method thereof | Elite Pharmaceutical Solution Inc. (US) | 2023-08-15 | — | — | US | claimed |
| CN-115715184-A | Ticagrelor oral dosage form and preparation method thereof | 赛乐医药科技有限公司 | 2023-02-24 | — | — | CN | claimed |
| WO-2022271167-A1 | ORAL DOSAGE FORM OF TICAGRELOR AND PREPARATION METHOD THEREOF | Elite Pharmaceutical Solution Inc. (US) | 2022-12-29 | — | — | WO | claimed |
| US-20220409545-A1 | ORAL DOSAGE FORM OF TICAGRELOR AND PREPARATION METHOD THEREOF | Elite Pharmaceutical Solution Inc. (US) | 2022-12-29 | — | — | US | claimed |
| CN-114058279-A | Curved screen protective film, preparation method and application thereof | 安徽屹珹新材料科技有限公司 | 2022-02-18 | — | — | CN | claimed |
| CN-107936186-B | 3D printing wire and preparation method thereof | 中国石油化工股份有限公司 | 2020-06-09 | — | — | CN | claimed |
| EP-1335045-B1 | THERMOPLASTIC CELLULOSE DERIVATIVE COMPOSITION AND FIBER COMPRISING THE SAME | TORAY INDUSTRIES (JP) | 2016-12-28 | — | — | EP | claimed |
| WO-2013168177-A2 | OSMOTICALLY CONTROLLED DRUG DELIVERY SYSTEMS | RUBICON RESEARCH PRIVATE LIMITED (IN) | 2013-11-14 | — | — | WO | claimed |
| US-8529955-B2 | Methods of treatment using a gastric retained gabapentin dosage | DEPOMED, INC. (US) | 2013-09-10 | — | — | US | claimed |
| EP-0626986-B1 | AQUEOUS DISPERSION USEFUL IN COATINGS CONTAINING HYDROLYZED CELLULOSE ESTER AND ACRYLIC RESIN | EASTMAN CHEM CO (US) | 1996-03-20 | — | — | EP | claimed |
| EP-0626986-A1 | AQUEOUS DISPERSION USEFUL IN COATINGS CONTAINING HYDROLYZED CELLULOSE ESTER AND ACRYLIC RESIN. | EASTMAN CHEM CO (US) | 1994-12-07 | — | — | EP | claimed |
| US-5334638-A | Aqueous dispersion useful in coatings containing hydrolyzed cellulose ester and acyrlic resin | EASTMAN CHEMICAL COMPANY (US) | 1994-08-02 | — | — | US | claimed |
| WO-1993014168-A1 | AQUEOUS DISPERSION USEFUL IN COATINGS CONTAINING HYDROLYZED CELLULOSE ESTER AND ACRYLIC RESIN | EASTMAN KODAK COMPANY (US) | 1993-07-22 | — | — | WO | claimed |
| EP-0227093-B1 | CELLULOSIC BINDER FOR DYE-DONOR ELEMENT USED IN THERMAL DYE TRANSFER | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1990-11-07 | — | — | EP | claimed |
| US-4700207-A | CELLULOSE TRIACETATE OR CELLULOSE MIXED ESTER | EASTMAN KODAK COMPANY (US) | 1987-10-13 | — | — | US | claimed |
| EP-0227093-A2 | Cellulosic binder for dye-donor element used in thermal dye transfer | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1987-07-01 | — | — | EP | claimed |
| US-4111203-A | OSMOTIC SYSTEM WITH MEANS FOR IMPROVING DELIVERY KINETICS OF SYSTEM | ALZA CORPORATION (US) | 1978-09-05 | — | — | US | claimed |
| US-4111202-A | OSMOTIC SYSTEM FOR THE CONTROLLED AND DELIVERY OF AGENT OVER TIME | ALZA CORPORATION (US) | 1978-09-05 | — | — | US | claimed |
| US-4058122-A | Osmotic system with laminated wall formed of different materials | ALZA CORPORATION (US) | 1977-11-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11723873-B2 | Oral dosage form of ticagrelor and preparation method thereof | TMEM165, ABCB11, ABCG2 | ESR1 1758/4885AKR1B1 2759/4885GPR84 956/4885 |
| US-20220409545-A1 | ORAL DOSAGE FORM OF TICAGRELOR AND PREPARATION METHOD THEREOF | TMEM165, ABCB11, ABCG2 | ESR1 1758/4885AKR1B1 2759/4885GPR84 956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.